Amplified benefit of Clopidogrel versus Aspirin in patients with diabetes mellitus

American Journal of Cardiology

Volumn 90, Issue 6, 2002, Pages 625-628

  Bhatt, Deepak L ^a   Marso, Steven P ^b   Hirsch, Alan T ^c   Ringleb, Peter A ^d   Hacke, Werner ^d   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; INSULIN; PLACEBO; PROTEIN INHIBITOR;

ADULT; AGE; ANALYSIS; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHI SQUARE DISTRIBUTION; CLAUDICATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTHESIS; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; RACE; RECURRENT DISEASE; REVASCULARIZATION; RISK; SEX; THROMBOCYTE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; WEIGHT;

AGED; ASPIRIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT READMISSION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0037106972     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02567-5     Document Type: Article

References (20)

1. Mak K.H., Moliterno D.J., Granger C.B., Miller D.P., White H.D., Wilcox R.G., Califf R.M., Topol E.J. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 30:1997;171-179.
2. Berger A.K., Breall J.A., Gersh B.J., Johnson A.E., Oetgen W.J., Marciniak T.A., Schulman K.A. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol. 87:2001;272-277.
3. Aronson D., Rayfield E.J., Chesebro J.H. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 126:1997;296-306.
4. Gowda M.S., Vacek J.L., Hallas D. One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty. Am J Cardiol. 81:1998;1067-1071.
5. Barsness G.W., Peterson E.D., Ohman E.M., Nelson C.L., DeLong E.R., Reves J.G., Smith P.K., Anderson R.D., Jones R.H., Mark D.B., Califf R.M. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 96:1997;2551-2556.
6. Abizaid A., Kornowski R., Mintz G.S., Hong M.K., Abizaid A.S., Mehran R., Pichard A.D., Kent K.M., Satler L.F., Wu H., Popma J.J., Leon M.B. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 32:1998;584-589.
7. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
8. Silva J.A., Escobar A., Collins T.J., Ramee S.R., White C.J. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation. 92:1995;1731-1736.
9. Davi G., Gresele P., Violi F., Basili S., Catalano M., Giammarresi C., Volpato R., Nenci G.G., Ciabattoni G., Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 96:1997;69-75.
10. Knobler H., Savion N., Shenkman B., Kotev-Emeth S., Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res. 90:1998;181-190.
11. Tschoepe D., Driesch E., Schwippert B., Lampeter E.F. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia. 40:1997;573-577.
12. Tschoepe D., Rauch U., Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res. 29:1997;631-635.
13. Shechter M., Merz C.N., Paul-Labrador M.J., Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol. 35:2000;300-307.
14. The Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death myocardial infarction and stroke in high risk patients. BMJ. 324:2002;71-86.
15. Bhatt D.L., Marso S.P., Lincoff A.M., Wolski K.E., Ellis S.G., Topol E.J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 35:2000;922-928.
16. Marso S.P., Lincoff A.M., Ellis S.G., Bhatt D.L., Tanguay J.F., Kleiman N.S., Hammoud T., Booth J.E., Sapp S.K., Topol E.J. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy . Circulation. 100:1999;2477-2484.
17. Roffi M., Chew D.P., Mukherjee D., Bhatt D.L., White J.A., Heeschen C., Hamm C.W., Moliterno D.J., Califf R.M., White H.D., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 104:2001;2767-2771.
18. CAPRIE Steering Committee . A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 348:1996;1329-1339.
19. Bhatt D.L., Hirsch A.T., Ringleb P.A., Hacke W., Topol E.J. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J. 140:2000;67-73.
20. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502.